Evidence map›Paper›PMID 42337956›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Leonard Pieperhoff, Luigi Lorenzini, Francisco Almeida, Mario Tranfa, Ariane Bollack, Prithvi Arunachalam, Federico Masserini, Robin Wolz, Sylke Grootoonk, Craig Ritchie and 25 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Leonard PieperhoffDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0009-0003-9003-4588
Luigi LorenziniDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-9756-881X
Francisco AlmeidaLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.ORCID https://orcid.org/0000-0002-8404-4136
Mario TranfaDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-4451-4746
Ariane BollackGE HealthCare, Amersham, UK.ORCID https://orcid.org/0000-0002-9169-7530
Prithvi ArunachalamDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-0798-6250
Federico MasseriniDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-0746-7426
Robin WolzIXICO plc London, London, UK.
Sylke GrootoonkIXICO plc London, London, UK.ORCID https://orcid.org/0009-0009-1140-8283
Craig RitchieScottish Brain Sciences, Edinburgh, UK.ORCID https://orcid.org/0000-0002-6202-6906
Mercè BoadaAce Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain.ORCID https://orcid.org/0000-0003-2617-3009
Marta MarquiéAce Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain.ORCID https://orcid.org/0000-0002-0660-0950
Jort VijverbergBrain imaging, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Rik VandenbergheLaboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0001-6237-2502
Bernard J HanseeuwDepartment of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.ORCID https://orcid.org/0000-0002-3102-6778
Pablo Martinez-LageCenter for Research and Advanced Therapies. CITA Alzheimer Foundation, Donostia-San Sebastián, Spain.ORCID https://orcid.org/0000-0001-5404-9967
Pierre PayouxToNIC Toulouse NeuroImaging Center, Université Toulouse 3, Inserm, Toulouse, France.ORCID https://orcid.org/0000-0002-1374-1620
Pieter Jelle VisserBrain imaging, Amsterdam Neuroscience, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0001-8008-9727
Michael SchöllDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID https://orcid.org/0000-0001-7800-1781
Giovanni B FrisoniHôpitaux Universitaires de Genève, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-7075-7082
Matteo PardiniDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.ORCID https://orcid.org/0000-0002-4740-1982
Luca RoccatagliaDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Andrew W StephensLife Molecular Imaging GmbH, Berlin, Germany.
Chris BuckleyGE HealthCare, Amersham, UK.
Gill FarrarGE HealthCare, Amersham, UK.
Frank JessenDepartment of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany.
Juan Domingo GispertBarcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.ORCID https://orcid.org/0000-0002-6155-0642
Gemma SalvadóBarcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.ORCID https://orcid.org/0000-0002-5210-9230
Emma S LuckettDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-1777-4742
Henk-Jan Mm MutsaertsDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-0894-0307
Alle Meije WinkDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-8197-0118
Lyduine E CollijDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0001-6263-1762
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-3543-3706
Tiago Gil OliveiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.ORCID https://orcid.org/0000-0003-0509-0562
AMYPAD consortium

Funding

Alzheimer Nederland WE.03-2024-27Alzheimer's Disease Data Initiative (ADDI)European Federation of Pharmaceutical Industries and AssociationsEuropean Union's Horizon 2020 Research and Innovation ProgrammeInnovative Medicines Initiative (IMI) 2 Joint Undertaking 115952
6 · The paper itself

Abstract

introductionEarly Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than classical morphometry.

methodsWe analyzed cross-sectional MRI and amyloid-β (Aβ) positron emission tomography (PET) data from 1323 non-demented AMYPAD participants. Cortical volume, thickness, gray-white matter contrast (GWC), and mean diffusivity (MD) were related to global Aβ burden and estimated time to Aβ-positivity using regression, correlation, and change-point analyses.

resultsMicrostructural measures showed stronger age associations than macrostructural measures, whereas all measures were unaffected by apolipoprotein E (APOE) -ε4 carriership. GWC and MD showed minimal overlap with volume and thickness. Higher Aβ burden was most strongly associated with reduced GWC and cortical thinning. Change-point analyses showed GWC alterations preceded Aβ-positivity by several years. DISCUSSION: Cortical microstructural MRI, particularly GWC, changes earlier than atrophy and may serve as an early in vivo marker of AD pathology.

Indexed as

Amyloid beta-PeptidesCerebral CortexGray MatterWhite MatterAgedAged, 80 and overAtrophyCross-Sectional StudiesFemaleHumansMagnetic Resonance ImagingMalePositron-Emission TomographyAmyloid beta-Peptidesdisease progressionMRIneuroimagingPETpreclinical Alzheimer's diseaseSILA

Identifiers

PMID42337956
PMCPMC13290647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.